Lung cancer is one of the most commonly diagnosed cancers worldwide and a leading cause of cancer-related mortality. Among its subtypes, non-small cell lung cancer (NSCLC) accounts for approximately 80–85% of all cases and demonstrates the highest response rates in the field of immunotherapy, making it a key focus for novel drug development.
However, predicting drug responsiveness has been challenging due to variability between patients. Lambda Biologics’ patient-derived organoids address this issue by reflecting the unique characteristics of individual patients. These organoids allow for the evaluation of drug responsiveness and differences based on patient diversity, providing valuable insights into personalized treatment strategies.